Zinc prices soared over the last few days after top consumer China increased imports of the metal in wake of the country’s halting production as part of an environmental crackdown on the local steel industry. The Asian nation’s move to curb zinc and nickel production is likely to have a significant impact on global supply, with inventories already under pressure from growing demand and currently at about 342,675 tons (roughly 20 percent lower than last year), according to Reuters (http://dtn.fm/gP0yM). Zinc exploration corporations such as Vancouver-based Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) are already exploring ways to step up efforts to find deposits so as to help meet the global demand for zinc.

Refined zinc imports to China jumped 21 percent year-over-year last month, reaching 47,469 tons (http://dtn.fm/H9mbb). Similarly, shipments of zinc ore and concentrates increased by 44 percent, Reuters said. This led to a significant increase in zinc prices, with the London Metal Exchange benchmark zinc closing up one percent at $2,658 per ton earlier this week – the highest since the beginning of the month.

Nickel prices also soared to $9,395, the highest in three weeks, as a result of growing Chinese imports. The halt in Chinese nickel production is unlikely to have a major impact, since the country accounts for only four percent of global supply. The situation, however, is significantly different when it comes to zinc, as the Asian nation accounted for at least 38 percent of global production before the crackdown. Both nickel and zinc are used in the steel manufacturing process – zinc for galvanized steel and nickel for stainless steel.

It is yet unclear how much of the country’s zinc and nickel production will be affected by the crackdown, but industry sources say the government is shutting down all steel mills that emit excessive pollution, along with zinc and nickel mining operations. Several of these operations might be reopened if they are found in compliance with environmental regulations, the sources added.

China’s move is likely to drive zinc demand even higher. According to the International Lead and Zinc Study Group, demand for the metal is already exceeding supply, and the difference is expected to reach 226,000 tons this year (http://dtn.fm/Lb7BC).

To help meet the rising demand, Canada’s Kootenay Zinc Corp. has already taken steps to expand its exploration program at its Sully property in British Columbia. The property is located near the legendary Sullivan Mine, which was one of the world’s largest reserves of zinc, with an output of over 17 million tons of zinc and lead until it was closed down in 2001. Kootenay’s Sully Project is located 18 miles from Sullivan, and both properties share different environments of the same basin.

For more information, visit the company’s website at www.KootenayZinc.com

Let us hear your thoughts: Kootenay Zinc Corp. Message Board

The global mobile revolution continues to accelerate. It’s estimated that, currently, about 4.8 billion individuals globally use a mobile phone, with about 2.3 billion of them being smart phone users. Smartphone subscribers now represent over half of the global mobile population. Mobile devices are fast becoming the go-to technology, even in mature economies where people can use alternative devices at home. Expanded mobile usage even engenders and propagates new behavior sets among consumers.

More mobile usage even drives the usage of mobile devices to make purchases. Approximately $37 billion in mobile transactions occurred in 2015, and that total is expected to explode to over $800 billion by 2019. Like the mobile phones and devices themselves, mobile transactions and payments will soon be commonplace.

Paying for transactions with mobile devices has taken off as a convenient and constructive option for both consumers and merchants. Consumers find it easier to rely on their phones for payments, while mobile point-of-sale transactions give merchants the ability to integrate loyalty and incentive programs into mobile payment applications, track customer trends and inventory, increase check-out speed and save money on credit card fees.

Net Element (NASDAQ: NETE) has been at the vanguard of facilitating this mobile point-of-sale (m-POS) boom, providing speed, security, accuracy, value-add and the convenience of mobile transactions. Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group. TOT Group companies include Aptito, Digital Provider, Restoactive, PayOnline and Unified Payments, which was named the fastest-growing private company in America in 2012 by Inc. Magazine.

Through its wholly owned group of companies, Net Element delivers tailored turnkey solutions that fit merchant needs. The company’s online and offline payment capabilities allow merchants to transact business anywhere, any way and at any time. Simultaneously, Net Element’s mobile payments and value-added transactional platforms deliver speed and convenience to mobile customers, giving them the ability to make purchases with just a few clicks on their mobile devices, and provide an alternative to cash payments.

For these and many other reasons, SeeThruEquity, a leading independent equity research firm, recently issued an update and reaffirmed its price target of $2.45 on shares of Net Element. It appears that the mobile payments boom could be very rewarding for Net Element and its shareholders.

For more information, visit www.NetElement.com

India Globalization Capital, Inc. (NYSE MKT: IGC) has named Craig Cheifetz, M.D., as an advisor to aid the company in its clinical trials in microbiology, immunology, neuroscience, and biotechnology. IGC is engaged in the development of cannabis-based therapies, which treat pain, terminal neurological and oncological diagnosis, PTSD, seizures, and other life altering issues. The company, based in Bethesda, Maryland, has a portfolio of patent filings for its phytocannabinoid-based treatments.

In a news release, Ram Mukunda, CEO of IGC, welcomed Cheifetz to the company’s advisory team, noting that he looks forward to Chiefetz’s contributions as IGC develops unique cannabis combination therapies.

Cheifetz is the Medical Director of Inova VIP 360, Northern Virginia’s Concierge Medicine Program. He is also Regional Dean at Virginia Commonwealth University Inova Fairfax Campus.

He received his M.D. from the State University of New York at Buffalo and also attended Georgetown University, where he trained in internal medicine. He was National GRMC Chairman from 2011 to 2013.

“We remain committed to accelerating our initiatives and building robust a portfolio of compounds to address large market conditions,” Mukunda noted in the release.

The company anticipates clinical trials in 2017 for several indications, including pain, a huge market. IGC has already filed for six patents in areas such as eating disorders and epilepsy, in addition to pain. It is working on several more filings for indications including depression, Alzheimer’s and Parkinson’s disease. Its lead candidate is IGC-501, and it has filed patents for the candidate in the United States, Canada and Europe.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

It is a prime time to be in the zinc mining business, and Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) is poised to profit in the midst of a continuing global zinc shortage and simultaneously booming prices.

As recently reported (http://dtn.fm/7RcNS), the price of zinc rose to $1.17 per pound and $2,628 per metric ton as of May 2017, representing a 60 percent increase over the previous year’s prices. This exceeded already propitious predictions that a deeper worldwide shortage would send zinc prices soaring as high as $2,500 per metric ton over the course of 2017 (http://dtn.fm/Mgwq5).

The current imbalance in the global zinc market is partly attributed to the 2016 shutdown of a number of zinc mines in China — the world’s largest producer of zinc, as well as its biggest consumer. Major zinc mines in other parts of the world have been experiencing declining ore supplies, as well, which is further credited as contributing to the shortage.

Seeking to cash in on the current global zinc shortage and price hike and to help meet the growing demand, KTNNF recently reported that it is expanding its active search for zinc at its Sully Project, which is located in British Columbia, Canada, just 18 miles (30 kilometers) from the legendary Sullivan Mine. The company recently reported it has completed three exploration holes at the site and that its project team is extending its survey efforts to the property’s west anomaly, including conducting state-of-the-art gravity mapping.

The Sully Project boasts shared geologic features with the famed Sullivan Mine, and the sedimentary rocks that host the Sullivan Mine are present at Sully, representative of different environments of the same basin. So far, geologic data indicates that the Sully Project shares the same stratigraphic level at which the Sullivan Mine was deposited, and it appears to coincide with the East gravity anomaly at the Sully Project. A subtle lead-zinc soil anomaly could reflect leakage up faults and dispersion through thick till and alluvium from an entirely buried deposit. A Cominco airborne geophysical survey has shown two N-S trending magnetic anomalies underground that are up to almost two miles long (1.86), that are approximately 0.62 miles apart, and that are near-coincident with the gravity anomalies.

So far, drilling efforts at the Sully Project have been a very near miss, meaning a strike may not be far away. Initial surveying at the project indicated that drilling conducted in 2004 only narrowly missed a shallow mass there. Work performed since then indicated the target was deep. The target may have been missed by just 100 meters, according to downhole temperature and magnetic field readings taken in 2014. KTNNF has initiated a drilling program and is targeting this East mass, which has been confirmed and better defined by new gravity data.

For more information, visit the company’s website at www.KootenayZinc.com

Let us hear your thoughts: Kootenay Zinc Corp. Message Board

BioCorRx (OTCQB: BICX) is the owner and creator of an innovative addiction treatment program used by a network of independent treatment centers to improve the lives of their patients struggling with alcohol and opioid addictions. The BioCorRx® Recovery Program leverages an innovative, two-pronged approach that addresses the underlying physical and behavioral issues associated with these addictions. The first half of this approach relies on a highly effective, proprietary implant formulation of the FDA-approved medication naltrexone, for which BioCorRx holds worldwide license rights (excluding Australia and New Zealand). The second half focuses on a modular counseling program coupled with overlapping peer support that is tailored specifically for those afflicted with alcohol and opioid addictions, helping to prepare them both physically and mentally for a life without these often dangerous substances.

America’s opioid epidemic is an increasingly treacherous issue that affects millions of people across the country. Per data from the Centers for Disease Control and Prevention, more than half a million people in the United States died from drug overdose from 2000 to 2015. Of those, more than 60 percent were linked to an opioid. Likewise, deaths from prescription opioids have more than quadrupled since 1999, driven by a nearly identical spike in the amount of prescription opioids sold. The negative implications associated with this addiction include traumatic life events for the addicted and their loved ones, as well as monumental financial expense. A 2010 study conducted by the American Society of Addiction Medicine found that addiction costs an estimated $700 billion annually in the U.S. alone.

Treating this growing problem has proven difficult. In 2011, the Substance Abuse and Mental Health Services Administration reported that 23.5 million persons aged 12 or older, roughly 9.3 percent of the population, needed treatment for an illicit drug or alcohol abuse problem. Of those, only 11.2 percent received the vital treatment at a specialty facility. BioCorRx aims to close this gap by both operating specialty facilities to aid those in need and providing a more thorough treatment program that’s been shown to lower patient drop-out rates, due to reduced cravings, and increase compliance rates, through automatic medication delivery and discreet outpatient treatment options.

In recent months, BioCorRx, through its BioCorRx Pharmaceuticals subsidiary, has looked to continue building on this proven medication through the clinical development of BICX101, a sustained release, injectable naltrexone for the treatment of opioid and alcohol use disorders. In early April, the company announced that three different formulations of the drug candidate showed success in reaching 28 days of sustained release in its preclinical studies, including one with an injection volume of just one milliliter. Following this result, BioCorRx formally requested a pre-IND meeting with the U.S. Food and Drug Administration as it continues to conduct additional studies in order to compile more data points.

In a business update issued earlier this month, Lourdes Felix, CFO, COO and director of BioCorRx, noted the strength of the company’s balance sheet following a March equity financing of $940,000 with accredited investors, as well as an investment of $1.7 million from Alpine Creek Capital Partners. Capital stemming from these transactions is expected to allow BioCorRx to continue executing on its business plan, including completion of “a few rounds of preclinical studies of BICX101” and accelerated sales and marketing activities related to its BioCorRx Recovery Program.

A strong balance sheet isn’t the only aspect of BioCorRx’s growth strategy about which prospective shareholders should be particularly optimistic. On May 16, the company announced its submission of a listing application for the Nasdaq Capital markets. The move comes less than two months after OTC Markets Group (OTCQX: OTCM) welcomed BioCorRx to the OTCQB Venture Market, which it reserves for early-stage and developing companies that are current in their reporting and undergo an annual verification and management certification process. The company will be required to meet a number of Nasdaq listing requirements in order to complete the uplist, but CFO Felix noted that members of BioCorRx’s management team “look forward to the prospect of a NASDAQ listing,” which they anticipate will “enhance BioCorRx’s visibility in the investment community to a larger market and provide for a broader, more diverse base of shareholders.”

Addressing the growing opioid epidemic in the United States, as well as lingering alcohol addiction issues, represents both an urgent call to action and a sizable market opportunity for companies offering proven effective treatment options. BioCorRx, through its innovative non-addictive medication-assisted treatment (MAT) program and promising clinical pipeline, represents an opportunity for the investment community to participate in the resolution of this crisis while capitalizing on the growth prospects of a leading edge health care solutions company.

For more information, visit www.BioCorRx.com

Savvy investors study multiple factors to identify potential stock winners. Stock screeners scan thousands of companies for insights and data to discern uncommon opportunities. The criteria utilized in a stock screening system is obviously influenced by an individual’s investment proclivities such as high yield, value, growth or price momentum, however, most stock screening systems are typically hybrids with blended criteria reflecting individual preferences and incorporating more than one investment style. P/E ratios, near zero beta, increased dividends, revenue growth and market growth are all employed to sift through over 100,000 public companies around the world and the nearly 6,000 U.S. listed companies.

All markets are addicted to growth. Growth is the elixir that drives markets and share prices of individual companies higher, and every stock screening system includes growth measurement variables. Growth is a testament to value creation. Current and future growth are prime indicators of potential future performance of a company’s share price. When looking for growth, it makes sense to look closely at companies that are not only growing rapidly but also growing rapidly in a rapidly growing market. With compound annual growth estimated at nearly 60 percent, the CBD (cannabidiol) industry is arguably the fastest growing market in the world. In fact, just five months ago Forbes called the CBD industry, “The Cannabis Market That Could Grow 700% by 2020” (http://dtn.fm/5vDve). That kind of growth can change a portfolio.

Currently legal in 16 states with more expected to follow, CBD oil is non-psychoactive and considered to have a broad range of medical benefits. Derived from hemp or marijuana plants, CBD has shown varying degrees of efficacy in treating epilepsy, Alzheimer’s disease, cirrhosis, pain, anxiety and stress.

CBD is obviously an explosive market opportunity. However, an even greater market opportunity lies outside the U.S., with over two billion Chinese speaking people. Acceptance and use of CBD oil is a natural fit with holistic Eastern-based medicine and an immense potential revenue generator for ChineseInvestors.com (OTCQB: CIIX). With two billion Chinese speaking people as its target market, ChineseInvestors.com recently executed a first-to-market milestone by creating the world’s only Chinese language, cannabinoid-based, therapeutic health products online store, www.ChineseCBDoil.com.

Historically, this specialized investment services company with 100,000+ users provided real-time market commentary, analysis, and education-related information in the Chinese language, as well as offered consultation, advertising, and public relations services. Now, the 18-year-old company is at the forefront of marketing and selling hemp-based food and beverages and hemp-derived CBD to Chinese-speaking consumers worldwide through its online store.

A recent research report by Consilium Global Research (http://dtn.fm/SA4bH) projects ChineseInvestors.com to grow at a compound annual growth rate (CAGR) of approximately 100% through 2020. Consilium sees CIIX going through immense transformation this year as it pursues a larger stake in the global cannabis market. Before long, ChineseInvestors.com should pop up on multiple stock screeners, as it’s growing rapidly in a rapidly growing market.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

Moxian, Inc. (NASDAQ: MOXC) has solidified its financial position as it competes in the massive Chinese sector of online-to-offline marketing. SeeThruEquity (http://nnw.fm/qTeF0) projected that the company could attain revenues of $24.1 million and net income of $4.5 million in FY 2018 as the O2O market is estimated to reach $48 billion in 1H17, according to investor materials provided by Moxian. One caveat to SeeThruEquity’s projections was for Moxian to demonstrate its ability to raise additional capital to finance its ambitious plans to compete in such a large market.

The high technology Shenzhen, China-based company netted some $8.5 million in an equity offering, at $4 per share, late in 2016 that resulted in its NASDAQ uplisting. In its SEC 10-Q filing of May 12, 2017, for the three-month period ended March 31, 2017 (http://nnw.fm/1xrKA), the firm additionally disclosed that it had received funds in a series of loans during the six months ended March 31, 2017.

The company is development stage and is building its infrastructure and staffing as it plans to execute its marketing strategy to take its two O2O mobile platforms from no charge to paid. Its Moxian+ is a paid business platform, with the firm’s immediate focus on converting its some 30,000 small market enterprise (SME) customers to paid. Similarly, it is attempting to convert its some 300,000 consumers on the Moxian User app from free to paid. Revenue streams foreseen by Moxian additionally include subscription revenues, transaction fees, mobile advertising, licensing fees, OEM and distribution charges.

SeeThruEquity was intrigued by the size of China’s O2O market and Moxian’s ambitious growth strategy, and it cautioned that the firm would require additional capital sources to finance and execute its strategy. The latest 10-Q by Moxian exhibited the firm’s ability to raise additional capital, enabling it to invest in more infrastructure and sales efforts.

During the six months ended March 31, 2017, the company received approximately $3.2 million from various related party loans and repaid a majority of all related party loans of approximately $5.6 million with IPO proceeds, the 10-Q filing said. Shenzhen Bayi Consulting Co., Limited and Moxian agreed to a series of loans aggregating $2.6 million unsecured, without interest or due on demand terms, to a subsidiary, Moxian Shenzhen. An earlier loan of $96,190 was made to Moxian by Bayi under the same terms. Vertical Venture Capital Group in this period made loans to subsidiary Moxian HK, with the same terms, in the aggregate of $553.8 million. Moxian HK partially repaid the loans as the company invested the funds internally.

Additionally, the SEC 10-Q stated that the company plans to bolster its future cash flows through additional related party financing and public and private placements.

For more information, visit www.Moxian.com

Looking to gain an advantageous foothold in the burgeoning medical marijuana market, India Globalization Capital, Inc. (NYSE MKT: IGC) is developing innovative cannabis-based combination therapies that have application for both humans and animals. The company’s focus is on treating pain, post-traumatic stress disorder (PTSD), chronic and terminal neurological and oncological diagnoses, cachexia, and other life-altering medical conditions.

IGC continues developing a portfolio of patent filings for phytocannabinoid-based treatments and has filed six patents to date. The company currently has three products in pre-clinical trials: IGC-501 for treatment of neuropathic pain in adult humans, IGC-502 for treatment of seizures in animals, and IGC-504 for treatment of cachexia in humans and animals.

Two of IGC’s patent filings, IGC-502 and IGC-505, are for combination therapies to treat seizures in dogs and cats, which represents a remarkably large market. Statistics show that between one percent and over five percent of dogs in the United States have some kind of seizure disorder. Certain dog breeds with hereditary epilepsy may have up to 15-20 percent incidence of seizures.

IGC’s novel therapy uses cannabinoid extracts in combination with other drugs to treat seizures in both dogs and cats, and this therapy has potential for application in humans, as well. The therapy can be administered through a variety of delivery technologies.

Operating on the belief that expanding cannabis legalization will create explosive demand for cannabinoid-based pharmaceutical therapies and related technologies and services, IGC is racing to be at the head of the pack and to be a first mover in the marijuana space by developing novel therapies, filing patent applications, and acquiring technologies from related industries that can cross over to cannabis as soon as permitted by federal law.

The company largely employs an outsourced model and has formed strategic alliances with doctors and scientists with expertise in central and peripheral nervous system disorders, the FDA process, and in pharmaceutical, nutraceutical and veterinarian trials. IGC also continues seeking information exchanges with medical cannabis dispensaries, doctors, research scientists, biotech companies, and medical and business professionals within the cannabinoid space, placing great value on collaborative research that can aid in the commercialization of products and in locating new ways to help patients — both human and animal — benefit from cannabinoids.

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

Slowly but surely cannabis is losing the stigma that has plagued it for close to one hundred years. Even some who frown on its use for recreational purposes are willing to consider that there may be therapeutic benefits in extracts of the cannabis sativa plant and so, increasingly, cannabinoids are being investigated to determine their effectiveness to treat a variety of debilitating medical conditions. Cannabinoid pharma is emerging as an entirely new industry segment in pharmaceuticals, and, as it does so, one innovative research company is blazing a trail in this new market by creating a niche of its own. India Globalization Capital, Inc. (NYSE MKT: IGC) has created its own space in pharmaceuticals. The Bethesda, Maryland-based company is a first mover in “combination therapies” that merge cannabinoids with existing drugs to provide more effective remedies.

IGC is not only a first mover in combination therapies; the company is also a fast mover. To date, IGC has dispatched six provisional patent filings to the U.S. Patent and Trademark Office for the indications of pain, medical refractory epilepsy, seizures, cachexia and eating disorders. Together, the remedies for these conditions present huge market opportunity, and IGC’s current low valuation versus comparable cannabis companies represents an important alert for all investors in this burgeoning industry.

IGC-501 is being developed to combat pain. The pain market represents a significant component of the health care system, with The Journal of Pain reporting in September 2012 that the annual estimated national cost of pain ranges from $560 billion to $635 billion, a figure that exceeds the cost of treating all other priority health conditions. Also, a NetworkNewsWire report on data released by Transparency Market Research estimates the global pain management therapeutics market will have a 3.7 percent CAGR through 2024, to reach $83.0 billion (http://dtn.fm/cMh1z).

Chronic pain takes such an exacting toll on the nation’s health that the American Pain Society has recommended pain be characterized as a fifth ‘vital sign’, along with body temperature, pulse rate, respiratory rate and blood pressure. Pain treatment can save lives. Terminal illnesses are often accompanied by levels of pain so intense and difficult to treat that death seems preferable. In addition, arthritis has been particularly problematic for women, according to the Arthritis Foundation, which reports that since 1999 there has been a 22 percent increase in the number of women who attribute their disability to arthritis.

As awareness of the effects of chronic pain has grown, increasingly powerful drugs such as morphine, codeine, and hydrocodone are being prescribed. However, these opioids are treacherously addictive and their use is often subverted from pain relief, making their way into recreational use. According to the Centers for Disease Control (CDC), 29,000 Americans die every year from opioid-related overdoses. This alarming statistic shows the pressing need for less addictive analgesics like IGC-501.

IGC-503 tackles refractory epilepsy, which affects about 50 million in the U.S. alone. Refractory epilepsy refers to cases of epilepsy that are unresponsive to current medications. Also in the pipeline is IGC-504, intended for those who suffer from cachexia, known as wasting syndrome. About 1.3 million in the U.S. experience cachexia associated with cancer, multiple sclerosis (MS), Parkinson’s, HIV/AIDS and other devastating maladies. In addition, there is IGC-506, designed to combat eating disorders, which are said to affect about 30 million Americans (http://dtn.fm/2j6Pq). Two other patents, IGC-502 and IGC-505, are designed to treat epileptic seizures in dogs and cats.

On the release of its financial results for the third-quarter ended December 31, 2016, CEO Ram Mukunda stated, “In 2017, our goal is to accelerate the development of our cannabis-based therapy portfolio to support key indications such as pain, seizures, cachexia, PTSD, and depression. In tandem, we expect to initiate pre-clinical trials on IGC-501-pain, IGC-502-seizures and IGC-504-cachexia.”

For more information, visit the company’s website at www.IGCinc.us

Let us hear your thoughts: India Globalization Capital, Inc. Message Board

Net Element, Inc. (NASDAQ: NETE), for the three months ended March 31, 2017, enjoyed over 20% growth in revenues to $13,561,941, versus $11,261,059 for the same period a year earlier. North America Transaction Solutions, one of three operating segments of the global financial company, drove the firm’s growth, generating 81% of total sales compared to 70% during the same period of the prior year.

Net Element is a financial technology group that processes global transactions in an omni-channel environment in what is becoming a world of cashless transaction processing. The company processes electronic payments from point-of-sale and mobile devices.

Net revenues for the company were generated principally by payment processing fees in North America, where transactions jumped 40%, exhibiting organic growth, according to Zacks SCR Digest (http://nnw.fm/mTJ49). In 2016, Net Element recorded a 54% jump in North America to $42.1 million. That accounted for about 78% of total company sales for the year.

In the first quarter of 2017, North American Transactions increased their dominance of company sales — contributing 81% of Net Element sales. At the same time, the North American segment maintained its gross margin performance — contributing 14% for the first quarter of 2017 versus 15% during the same period of the prior year.

As the North American segment was cementing its hold on company revenues, mobile solutions continued their decline. In the first quarter of 2016, mobile solutions contributed 18% of company sales; that number fell to just 6% in the first quarter of 2017. Its sales dropped from $1,993,504 in 2016 down to $856,993 in the first quarter of 2017.

As a result of that performance, Oleg Firer, CEO of Net Element, said in a news release, “We are undertaking several strategic changes in the mobile solutions segment, which should yield results in the third-quarter of this year.”

SeeThruEquity, in an April 12, 2017, updated research report (http://nnw.fm/fFPV7), projects the company’s sales in FY 2017 at $62.9 million.

For more information, refer to www.NetElement.com